CO2023009810A2 - Materiales y métodos para el seguimiento del cáncer mediante la administración de un anticuerpo anti-mcl1 - Google Patents

Materiales y métodos para el seguimiento del cáncer mediante la administración de un anticuerpo anti-mcl1

Info

Publication number
CO2023009810A2
CO2023009810A2 CONC2023/0009810A CO2023009810A CO2023009810A2 CO 2023009810 A2 CO2023009810 A2 CO 2023009810A2 CO 2023009810 A CO2023009810 A CO 2023009810A CO 2023009810 A2 CO2023009810 A2 CO 2023009810A2
Authority
CO
Colombia
Prior art keywords
methods
administering
materials
monitoring cancer
mcl
Prior art date
Application number
CONC2023/0009810A
Other languages
English (en)
Inventor
Agnieszka Kielczewska
Brian Chan
Michael C Boyle
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CO2023009810A2 publication Critical patent/CO2023009810A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La divulgación proporciona anticuerpos anti-Mcl-1 de cualquier forma, y fragmentos de los mismos, que se unen al antígeno con una unión inesperadamente alta a Mcl-1, proporcionando herramientas útiles en métodos de seguimiento de células cancerosas que expresan Mcl-1 y métodos de tratamiento de cánceres, particularmente cánceres sanguíneos, que comprenden dichas células cancerosas.
CONC2023/0009810A 2021-01-29 2023-07-25 Materiales y métodos para el seguimiento del cáncer mediante la administración de un anticuerpo anti-mcl1 CO2023009810A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143682P 2021-01-29 2021-01-29
PCT/US2022/014401 WO2022165240A1 (en) 2021-01-29 2022-01-28 Materials and methods for monitoring cancer by administering an anti-mcl1 antibody

Publications (1)

Publication Number Publication Date
CO2023009810A2 true CO2023009810A2 (es) 2023-08-09

Family

ID=82654972

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0009810A CO2023009810A2 (es) 2021-01-29 2023-07-25 Materiales y métodos para el seguimiento del cáncer mediante la administración de un anticuerpo anti-mcl1

Country Status (14)

Country Link
US (1) US20240117069A1 (es)
EP (1) EP4284826A1 (es)
JP (1) JP2024508222A (es)
KR (1) KR20230135087A (es)
CN (1) CN116806156A (es)
AU (1) AU2022214936A1 (es)
CA (1) CA3203780A1 (es)
CL (1) CL2023002189A1 (es)
CO (1) CO2023009810A2 (es)
CR (1) CR20230388A (es)
IL (1) IL303844A (es)
MX (1) MX2023008971A (es)
PE (1) PE20231731A1 (es)
WO (1) WO2022165240A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086321A1 (en) * 1993-02-02 2002-07-04 Craig Ruth W. Myeloid cell leukemia associated gene MCL-1
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
NZ597767A (en) * 2007-05-21 2013-06-28 Bristol Myers Squibb Co Antibodies to IL-6 and use thereof
BR112016015589A2 (pt) * 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
US20200399373A1 (en) * 2018-02-14 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule and combination
JP7205691B2 (ja) * 2019-01-23 2023-01-17 ウシオ電機株式会社 抗イヌプロカルシトニン抗体及びこれを用いた検査用キット

Also Published As

Publication number Publication date
AU2022214936A1 (en) 2023-06-29
CR20230388A (es) 2023-10-05
KR20230135087A (ko) 2023-09-22
JP2024508222A (ja) 2024-02-26
IL303844A (en) 2023-08-01
WO2022165240A1 (en) 2022-08-04
CA3203780A1 (en) 2022-08-04
US20240117069A1 (en) 2024-04-11
CL2023002189A1 (es) 2024-03-01
AU2022214936A9 (en) 2023-08-17
PE20231731A1 (es) 2023-10-26
CN116806156A (zh) 2023-09-26
MX2023008971A (es) 2023-08-15
EP4284826A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
AR114002A1 (es) Anticuerpos a lilrb2
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
UY38236A (es) COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
CL2019002428A1 (es) Anticuerpos y fragmentos anti-vista. (divisional solicitud 201601646).
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
CR20190079A (es) Anticuerpos anti-tim-3
BR112019005697A2 (pt) anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
UY37141A (es) Anticuerpos dirigidos a tigit
PE20181399A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
CL2018002034A1 (es) Proteínas de unión a antígeno que se unen a pd-l1.
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
UY37761A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CO2022009744A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
DOP2023000158A (es) Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
CL2023002326A1 (es) Anticuerpos contra la proteína espicular de coronavirus
CL2021001813A1 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
ECSP22094536A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
CL2020001726A1 (es) Anticuerpos monoclonales y métodos para utilizar los mismos.